Видео ютуба по тегу Rana Mckay

Meet Rana R. McKay, MD: Medical Oncologist
Meet Rana R. McKay, MD: Medical Oncologist
Dr. Rana McKay: Inspiring Journey in GU Oncology | OncoInfluencers
Dr. Rana McKay: Inspiring Journey in GU Oncology | OncoInfluencers
Rana McKay on the Future of Prostate Cancer Care
Rana McKay on the Future of Prostate Cancer Care
ASCO® GU Data Updates: KEYNOTE-564 and CheckMate 914
ASCO® GU Data Updates: KEYNOTE-564 and CheckMate 914
What is Triplet Therapy, Benefits & Side Effects for Advanced Prostate Cancer I Dr. Rana McKay – 145
What is Triplet Therapy, Benefits & Side Effects for Advanced Prostate Cancer I Dr. Rana McKay – 145
Dr. Rana McKay on the Current Treatment Paradigm for Metastatic RCC
Dr. Rana McKay on the Current Treatment Paradigm for Metastatic RCC
An Interview with Dr. Rana McKay
An Interview with Dr. Rana McKay
Androgen Deprivation Therapy ADT in Prostate Cancer Treatment with Rana Mckay, MD EP 63
Androgen Deprivation Therapy ADT in Prostate Cancer Treatment with Rana Mckay, MD EP 63
Dr. Rana McKay on Frontline Immunotherapy for Metastatic RCC
Dr. Rana McKay on Frontline Immunotherapy for Metastatic RCC
How to treat Prostate Cancer in 2024 with Dr. Rana McKay
How to treat Prostate Cancer in 2024 with Dr. Rana McKay
IPCSG March 16 2019 - Rana R. McKay, MD
IPCSG March 16 2019 - Rana R. McKay, MD
VIRO 2025 Kicked off, watch LIVE on OncoDaily TV
VIRO 2025 Kicked off, watch LIVE on OncoDaily TV
Rana McKay and Derek Johnston
Rana McKay and Derek Johnston
Rana McKay, MD, on the real world impact of immunotherapy when added to oral therapies for APC
Rana McKay, MD, on the real world impact of immunotherapy when added to oral therapies for APC
Rana McKay MD, explains approach to treating 2nd-line RCC patients who have received I-O combination
Rana McKay MD, explains approach to treating 2nd-line RCC patients who have received I-O combination
Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients
Rana McKay, MD, explains how to differentiate between TKIs available for renal cell cancer patients